Compare ATOM & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | STRO |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.6M | 85.0M |
| IPO Year | 2016 | N/A |
| Metric | ATOM | STRO |
|---|---|---|
| Price | $5.05 | $20.43 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | ★ 4.7M | 116.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,000.00 | N/A |
| Revenue This Year | $527.69 | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $0.52 |
| 52 Week High | $7.45 | $20.59 |
| Indicator | ATOM | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 73.10 |
| Support Level | $2.55 | $0.76 |
| Resistance Level | $5.26 | N/A |
| Average True Range (ATR) | 0.93 | 1.70 |
| MACD | 0.10 | 0.27 |
| Stochastic Oscillator | 54.15 | 94.68 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used transistor types in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, logic and processors, and SRAM.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.